Chwen-Cheng Chen

Title: Innovations in Cancer Immunotherapy by Chwen-Cheng Chen

Introduction

Chwen-Cheng Chen is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer immunotherapy, focusing on innovative methods to enhance immune responses against cancer.

Latest Patents

Chwen-Cheng Chen holds a patent for a groundbreaking method titled "Cancer immunotherapy by immune activation or immune modulation via Globo series antigens." This patent outlines a method of immunotherapy for cancer patients, which includes administering vaccines against Globo series antigens such as Globo H, Stage-specific embryonic antigen 3 (SSEA3), and Stage-specific embryonic antigen 4 (SSEA4). Specifically, the method involves administering Globo H-KLH (OBI-822) to patients with metastatic breast cancer. The patent also details a process for selecting suitable cancer patients for immunotherapy and provides therapeutic agents, including monoclonal antibodies (mAbs) that specifically bind to Globo series antigens and related biomarkers.

Career Highlights

Chwen-Cheng Chen is associated with Obi Pharma Inc., where he continues to advance research in cancer treatment. His work has been pivotal in developing therapies that target specific cancer antigens, thereby improving treatment outcomes for patients.

Collaborations

Chwen-Cheng Chen collaborates with notable colleagues such as Cheng-Der Tony Yu and Youe-Kong Shue, contributing to a dynamic research environment focused on innovative cancer therapies.

Conclusion

Chwen-Cheng Chen's contributions to cancer immunotherapy represent a significant advancement in the field, showcasing the potential of targeted therapies in improving patient outcomes. His innovative approaches continue to inspire further research and development in cancer treatment.